-+ 0.00%
-+ 0.00%
-+ 0.00%

GlaxoSmithKline rose 1% in early Wednesday trading. The company's dermoximab has been approved by the US FDA as an additional treatment twice a year for severe eosinophilic asthma; SWIFT clinical trials have shown that the drug can reduce the annual acute attack rate by up to 58% compared to placebo.

Zhitongcaijing·12/17/2025 15:33:02
Listen to the news
GlaxoSmithKline rose 1% in early Wednesday trading. The company's dermoximab has been approved by the US FDA as an additional treatment twice a year for severe eosinophilic asthma; SWIFT clinical trials have shown that the drug can reduce the annual acute attack rate by up to 58% compared to placebo.